Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Controlled Temperature Chain versus standard cold chain for HPV vaccination in Côte d’Ivoire
PACTR202503831711274Phase 3Not yet recruiting
- Sponsor
- Swiss Tropical and Public Health Institute
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Walrinvax in human papillomavirus infection (2 arms), sponsored by Swiss Tropical and Public Health Institute. Primary endpoint: HPV vaccination status. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Walrinvax
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on PACTR202503831711274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202503831711274.